Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus

Abstract

The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

1 - 26 . (canceled) 
     
     
         27 . A viscous liquid dosage form comprising fluticasone propionate in combination with 0.5 wt % to 10 wt % of sodium alginate as viscosity enhancer and other non-active ingredients, said non-active ingredients comprising:
 (i) a sweetener agent;   (ii) 0.1 wt % to 0.5 wt % of carbomer as suspending agent;   (iii) 0.001 wt % to 0.01 wt % of polysorbate 80 as wetting agent;   (iv) 0.06 wt % to 0.6 wt % of a mixture of methylparaben and propylparaben as preservative; and   (v) sodium hydroxide,   wherein the viscous liquid dosage form is formulated for oral administration, and   wherein the viscous liquid dosage form has a pH of about 6 to about 8.   
     
     
         28 . The viscous liquid dosage form of  claim 27 , wherein the sweetener agent is aspartame, cyclamate sodium, cyclamate calcium, acesulfame potassium, sucralose, saccharin sodium, xylitol, or sorbitol. 
     
     
         29 . The viscous liquid dosage form of  claim 27 , wherein the sweetener agent is sucralose. 
     
     
         30 . The viscous liquid dosage form of  claim 27 , comprising 0.05 wt % to 0.5 wt % of the sweetener agent. 
     
     
         31 . The viscous liquid dosage form of  claim 27 , further comprising 0.1 wt % to 1 wt % of a flavoring agent. 
     
     
         32 . The viscous liquid dosage form of  claim 27 , comprising 0.15 wt % to 0.4 wt % of methylparaben. 
     
     
         33 . The viscous liquid dosage form of  claim 27 , comprising 0.01 wt % to 0.1 wt % of propylparaben. 
     
     
         34 . The viscous liquid dosage form of  claim 27 , comprising 0.5 wt % of sodium alginate.